A powerful injection delivered directly into arthritic joints could cut pain levels for millions of sufferers.
Scientists have found a way to stop nerve cells in diseased joints sensing pain - without any side effects, the Daily Express reported.
They say their discovery could drastically cut the number of knee and hip replacements performed in Britain each year - currently around 160,000, and costing the NHS almost 200 million pounds.
Scientists from the Arthritis Research UK Pain Centre at Nottingham University targeted a nerve cell pain receptor called TRPV1.
Previous trials on osteoarthritis patients showed their pain could be cut by blocking the receptor using drugs called TRPV1 antagonists. But the patients experienced the side effect of hyper-thermia - overheating of the body - apparently in their digestive organs.
Neuroscience lecturer Dr Sara Kelly explained that the Nottingham team used a model of osteoarthritis pain to see if using the drugs within the joint itself would work better.
Dr Kelly said that by targeting the joint directly they did not see the side effect of hyperthermia.
The study is published in the journal Annals Of The Rheumatic Diseases.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
